Skip to content

Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases

Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07564908
Acronym
CRLM
Enrollment
64
Registered
2026-05-04
Start date
2018-01-01
Completion date
2030-12-30
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Neoplasms

Keywords

Colorectal cancer liver metastases, Histopathological growth patterns, Tumor microenvironment

Brief summary

Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases

Detailed description

This study aims to retrospectively analyze the status and spatial heterogeneity of the tumor microenvironment (TME) in liver metastases from patients with CRLM, as well as the association between HGPs at the tumor-liver interface and postoperative recurrence following resection of liver metastases. Furthermore, this study seeks to explore the underlying mechanisms through which HGPs influence patient prognosis.

Interventions

OTHERFormalin-fixed, paraffin-embedded (FFPE) sections of colorectal cancer liver metastases were stained with hematoxylin and eosin (H&E) and Multiplex immunohistochemistry (mIHC) staining.

Formalin-fixed, paraffin-embedded (FFPE) sections of colorectal cancer liver metastases were stained with hematoxylin and eosin (H\&E) and Multiplex immunohistochemistry (mIHC) staining.

Sponsors

Meng Qiu
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with CRLM who underwent R0 resection * Histologically or cytologically confirmed CRLM * Have sufficient liver metastasis tissue specimens available for analysis * Complete treatment and follow-up records

Exclusion criteria

* Patients did not undergo R0 resection * Postoperative specimens were unavailable * Clinical data were incomplete.

Design outcomes

Primary

MeasureTime frameDescription
OS(Overall survival)OS is defined as the time from the date of the first liver metastasis resection to death due to any cause or loss to follow-up, assessed up to 100 months.OS was defined as the time from the date of the first liver metastasis resection to death due to any cause or loss to follow-up.
RFS (Recurrence-free Survival)From the date of liver resection until the first occurrence of a measurable recurrence of the disease, or until death due to any cause (whichever occurs first), the assessment period can be up to 100 months.The definition of recurrence-free survival is the time from the liver surgery to the first imaging evidence showing disease recurrence or death due to any cause, whichever occurs first.
HGPs (Histopathological Growth Patterns)From the completion of HE staining to the failure of staining or the damage and loss of the slides, the assessment period can be up to 100 months.The histopathological growth pattern of the tumor-liver interface.
TME (Tumor Microenvironment)From the completion of mIHC staining to the failure of staining or the damage and loss of the slides, the assessment period can be up to 100 months.Multiplex immunohistochemistry (mIHC) staining was performed on FFPE sections of liver metastases using two panels (Panel 1: CD4, CD8A, Foxp3, PD-L1, Panck; Panel 2: CD68, CD163, FAP-α, α-SMA, Panck), encompassing a total of nine immune cell markers. Using QuPath pathology imaging software, tissue sections were divided into the tumor center (defined as regions \>500 μm from the liver-tumor interface) and the invasive tumor front (defined as a 1 mm region extending 500 μm on either side of the liver-tumor interface). Quantitative analysis of immune cell populations was performed in the tumor center, the invasive tumor front, and regions corresponding to different histopathological growth patterns.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026